Furthermore, dysregulation in ADORA1/ADORA2A expression was associated with glioma development, and a low level of ADORA1/ADORA2A expression could increase the susceptibility of tumor-associated epilepsy (Huang et al., 2016). This evidence concerns the gene ADORA1 and central nervous system cancer.